Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-119741 · Präparat HOS-095005
12
OESTROGEN-BASED CONTRACEPTIVES
Ethinylestradiol ethinylestradiol The combination of
0.035 mg once daily AUC ↑ 1.22 (1.13-1.31) oestrogen- and/or
Norethindrone Cmin ↔ 1.09 (1.01-1.18) progesterone-based
1 mg once daily Cmax ↑ 1.33 (1.21-1.46) contraceptives and
norethindrone INTELENCE can be used
AUC ↔ 0.95 (0.90-0.99) without dose adjustment.
Cmin ↓ 0.78 (0.68-0.90)
Cmax ↔ 1.05 (0.98-1.12)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
Ribavirin Not studied, but no interaction expected based The combination of
on the renal elimination pathway of ribavirin. INTELENCE and ribavirin
can be used without dose
adjustments.
Daclatasvir Not studied. Co-administration of etravirine Co-administration of
with daclatasvir may decrease daclatasvir INTELENCE and daclatasvir
concentrations. is not recommended.
Elbasvir/grazoprevir Not studied. Co-administration of etravirine Co-administration is
with elbasvir/grazoprevir may decrease elbasvir contraindicated (see
and grazoprevir concentrations, leading to section 4.3).
reduced therapeutic effect of
elbasvir/grazoprevir.
HERBAL PRODUCTS
St John’s wort Not studied. St John’s wort is expected to Combination not
(Hypericum perforatum)
decrease the plasma concentrations of recommended.
etravirine.
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin atorvastatin The combination of
40 mg once daily AUC ↓ 0.63 (0.58-0.68) INTELENCE and
Cmin ND atorvastatin can be given
Cmax ↑ 1.04 (0.84-1.30) without any dose
2-OH-atorvastatin adjustments, however, the
AUC ↑ 1.27 (1.19-1.36) dose of atorvastatin may
Cmin ND need to be altered based on
Cmax ↑ 1.76 (1.60-1.94) clinical response.
etravirine
AUC ↔ 1.02 (0.97-1.07)
Cmin ↔ 1.10 (1.02-1.19)
Cmax ↔ 0.97 (0.93-1.02)
Fluvastatin Not studied. No interaction between pravastatin Dose adjustments for these
Lovastatin and etravirine is expected. HMG Co-A reductase
Pravastatin Lovastatin, rosuvastatin and simvastatin are inhibitors may be necessary.
Rosuvastatin CYP3A4 substrates and co-administration with
Simvastatin etravirine may result in lower plasma
concentrations of the HMG Co-A reductase
inhibitor. Fluvastatin, and rosuvastatin are
metabolised by CYP2C9 and co-administration
with etravirine may result in higher plasma
concentrations of the HMG Co-A reductase
inhibitor.
H2-RECEPTOR ANTAGONISTS
Ranitidine etravirine INTELENCE can be
150 mg twice daily AUC ↓ 0.86 (0.76-0.97) co-administered with
Cmin ND H2-receptor antagonists
Cmax ↓ 0.94 (0.75-1.17) without dose adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) daclatasvir (HOS-119742) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) grazoprevir (HOS-108815) ranitidine (HOS-085660) norethindrone (HOS-088136) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage b4ae62f3b56de12cf8406dcb55d38bc3538cd806a08b537965c6bb7ead0cc339 · Zeichen 24913–29265 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120774 · Präparat HOS-095209
Medicinal products that elevate gastric pH:
Daily co-administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not
change the prasugrel active metabolite’s AUC and Tmax, but decreased the Cmax by 14% and 29%,
respectively. In the phase 3 clinical trial, Efient was administered without regard to co-administration
of a proton pump inhibitor or H2 blocker. Administration of the 60 mg prasugrel loading dose without
concomitant use of proton pump inhibitors may provide most rapid onset of action.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage f890338de42acf8500753110f843f50cd7e44ada27cfa068ebbecbcecc32525d · Zeichen 2418–2947 im Abschnitt
Wechselwirkungen · Iressa
IRESSA 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-121316 · Präparat HOS-095327
Substances that cause significant sustained elevation in gastric pH may reduce gefitinib plasma
concentrations and thereby reduce the efficacy of gefitinib. High doses of short-acting antacids may
have a similar effect if taken regularly close in time to administration of gefitinib. Concomitant
administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥ 5
resulted in a reduced mean gefitinib AUC by 47% in healthy volunteers (see section 4.4 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-07-17T11:35:00Z · SHA-256 3bcaef596cdab500a720486bec050bfa038a5c9ed552c9e5d531667fcd7af63e · Passage a9a690e9fb8e7ab8d81baea2d4f0fef8dac29f9981c10bc080596932a7ffbf74 · Zeichen 1996–2493 im Abschnitt
Wechselwirkungen · Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211903 · Präparat HOS-154784
The possibility of interactions with other medicinal products administered concurrently should be
considered, particularly when the main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine. The
nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are
unlikely to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) didanosine (HOS-085836) zidovudine (HOS-085837) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage f95f33741513a03415ee49d3475d877bb6b9081af94776eebfc6141682077199 · Zeichen 793–1329 im Abschnitt
Wechselwirkungen · Lamivudine Teva
Lamivudine Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211991 · Präparat HOS-154800
Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of
interactions with other medicinal products administered concurrently should be considered,
particularly when their main route of elimination is active renal secretion via the organic cationic
transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are
eliminated only in part by this mechanism and were shown not to interact with lamivudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) cimetidine (HOS-085835) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-07T02:00:00Z · SHA-256 7ebfd130ef9d9ca18166e2a55526570d39c018726558f43f8bad673f541d0883 · Passage 1675843e9b8449c95d3864ada4cae5935a283fe89e2d5c43d4283e20e5dae000 · Zeichen 221–693 im Abschnitt
Wechselwirkungen · Temomedac
Temomedac 5 mg hard capsules Temomedac 20 mg hard capsules Temomedac 100 mg hard capsules Temomedac 140 mg hard capsules Temomedac 180 mg hard capsules Temomedac 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-122291 · Präparat HOS-095503
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-03-28T02:00:00Z · SHA-256 f4d0129234cae9372d16371be7befb03cd6555ac814ca229be825f7d69ccb7d9 · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Temozolomide Accord
Temozolomide Accord 5 mg hard capsules. Temozolomide Accord 20 mg hard capsules. Temozolomide Accord 100 mg hard capsules. Temozolomide Accord 140 mg hard capsules. Temozolomide Accord 180 mg hard capsules. Temozolomide Accord 250 mg hard capsules. · Abschnitt 4.5 · PDF-Seite 7
HOS-212012 · Präparat HOS-154808
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-02T11:26:00Z · SHA-256 d5a737eecba60b68093f4466fc687af593eae980cbf153f31b54b82f3b09990b · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Temozolomide Teva
Temozolomide Teva 5 mg hard capsules Temozolomide Teva 20 mg hard capsules Temozolomide Teva 100 mg hard capsules Temozolomide Teva 140 mg hard capsules Temozolomide Teva 180 mg hard capsules Temozolomide Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-212044 · Präparat HOS-154816
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-05-16T02:00:00Z · SHA-256 9c0a97d9d4d48622c8615e39cfac79b61fd65905543c5f50ba2ebfd2a591854a · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Ibandronic Acid Teva
Ibandronic Acid Teva 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-212566 · Präparat HOS-154930
H2-antagonists or other medicinal products that increase gastric pH.
In healthy male volunteers and postmenopausal women, intravenous ranitidine caused an increase in
ibandronic acid bioavailability of about 20% (which is within the normal variability of the
bioavailability of ibandronic acid), probably as a result of reduced gastric acidity. However, no dosage
adjustment is required when Ibandronic Acid Teva is administered with H2-antagonists or medicinal
products that increase gastric pH.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-28T16:00:09Z · SHA-256 a77d86843d2ecd9a9cc76a7966a88b66429aafa008e6f882df206e72867ec593 · Passage 37429936a2eef909385e54afabc9afca31f9a39027ad13ad2d654c1f3a23d7f5 · Zeichen 1052–1548 im Abschnitt
Wechselwirkungen · Ibandronic Acid Teva
Ibandronic Acid Teva 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-212590 · Präparat HOS-154930
In healthy male volunteers and postmenopausal women, intravenous administration of ranitidine
caused an increase in ibandronic acid bioavailability of about 20%, probably as a result of reduced
gastric acidity. However, since this increase is within the normal variability of the bioavailability of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-28T16:00:09Z · SHA-256 a77d86843d2ecd9a9cc76a7966a88b66429aafa008e6f882df206e72867ec593 · Passage e2abc82733f359bd2c2393ff797f6552bb63b82fa230c0c04033e0f02aaf4e82 · Zeichen 2141–2439 im Abschnitt
Wechselwirkungen · Iasibon
Iasibon 50 mg film coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-124071 · Präparat HOS-095779
H2-antagonists or other medicinal products that increase gastric pH.
In healthy male volunteers and postmenopausal women, intravenous ranitidine caused an increase in
ibandronic acid bioavailability of about 20 % (which is within the normal variability of the
bioavailability of ibandronic acid), probably as a result of reduced gastric acidity. However, no dosage
adjustment is required when Iasibon is administered with H2-antagonists or medicinal products that
increase gastric pH.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T17:38:00Z · SHA-256 858d65121d0c57fc23c7219d9cfeb81383762c7e90e23c1b5a81b14cfe281605 · Passage 95b14c51580a958b86b397bcf240aec8a98e72b315118305f96aeacd81e00670 · Zeichen 1036–1520 im Abschnitt
Wechselwirkungen · Temozolomide Sun
Temozolomide SUN 5 mg hard capsules Temozolomide SUN 20 mg hard capsules Temozolomide SUN 100 mg hard capsules Temozolomide SUN 140 mg hard capsules Temozolomide SUN 180 mg hard capsules Temozolomide SUN 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-124739 · Präparat HOS-095929
In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the
extent of absorption of temozolomide or the exposure to its active metabolite monomethyl
triazenoimidazole carboxamide (MTIC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T14:25:00Z · SHA-256 ce7fa281f501d82cdf0ea3a5d6145085813b0d104ab4cef856da0017cf1b79ff · Passage ee289c2fa788917ac2b83776352d3a244ff18f6d1d1f0239d60402688d18e4d2 · Zeichen 0–230 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-213955 · Präparat HOS-155234
8
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
NARCOTIC ANALGESICS
Methadone* R(-) methadone AUC ↓ 16% No dose adjustments are required
60-100 mg once daily, R(-) methadone Cmin ↓ 22% when initiating co-administration of
individualised dose R(-) methadone Cmax ↓ 14% methadone with rilpivirine. However,
rilpivirine AUC ↔* clinical monitoring is recommended as
rilpivirine Cmin ↔* methadone maintenance therapy may
rilpivirine Cmax ↔* need to be adjusted in some patients.
* based on historic controls
ANTIARRHYTHMICS
Digoxin* digoxin AUC ↔ No dose adjustment is required.
digoxin Cmin NA
digoxin Cmax ↔
ANTICOAGULANTS
Dabigatran etexilate Not studied. A risk for increases in The combination of rilpivirine and
dabigatran plasma concentrations dabigatran etexilate should be used
cannot be excluded. with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) digoxin (HOS-086172) dabigatran (HOS-112096) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage a82647616d2369ed93f5c1c0ca58dde62668e3f570c10a0d9aee6e832fcc541a · Zeichen 14265–16215 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-214008 · Präparat HOS-155234
(reduced absorption due to gastric
pH increase)
Lansoprazole Not studied. Significant decreases
Rabeprazole in rilpivirine plasma concentrations
Pantoprazole are expected.
Esomeprazole
(reduced absorption due to gastric
pH increase)
H2-RECEPTOR ANTAGONISTS
Famotidine*# rilpivirine AUC ↓ 9% The combination of rilpivirine and
40 mg single dose taken rilpivirine Cmin NA H2-receptor antagonists should be used
12 hours before rilpivirine Cmax ↔ with particular caution. Only
rilpivirine H2-receptor antagonists that can be
Famotidine*# rilpivirine AUC ↓ 76% dosed once daily should be used.
40 mg single dose taken rilpivirine Cmin NA A strict dosing schedule, with intake of
2 hours before rilpivirine rilpivirine Cmax ↓ 85% H2-receptor antagonists at least
12 hours before or at least 4 hours
(reduced absorption due to gastric after rilpivirine should be used.
pH increase)
Famotidine*# rilpivirine AUC ↑ 13%
40 mg single dose taken rilpivirine Cmin NA
4 hours after rilpivirine rilpivirine Cmax ↑ 21%
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 127a046a3ba0f0f2919bad57eab9493f739a4627df3219ad6f8640932758cd01 · Zeichen 11316–13658 im Abschnitt
Wechselwirkungen · Buccolam
BUCCOLAM 2.5 mg oromucosal solution BUCCOLAM 5 mg oromucosal solution BUCCOLAM 7.5 mg oromucosal solution BUCCOLAM 10 mg oromucosal solution · Abschnitt 4.5 · PDF-Seite 5
HOS-124965 · Präparat HOS-095969
Cimetidine, ranitidine and omeprazole have been shown to reduce the clearance of midazolam and other
benzodiazepines and may potentiate their actions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-13T16:00:00Z · SHA-256 aca1e2a5d7d25b6e4740ff0245eafab8569c638d4fe76a1ae7ccc9e3ddb17e4d · Passage d41e6d95e58264d6fe476631828e269fc66a155d9d5da46eadf47922eb0b99af · Zeichen 1390–1540 im Abschnitt
Wechselwirkungen · Lojuxta
Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-127355 · Präparat HOS-096397
Weak CYP3A4 inhibitors are When administered with atorvastatin, the
expected to increase the exposure of dose of lomitapide should either be taken
lomitapide when taken 12 hours apart or be decreased by half (see
simultaneously. section 4.2). The dose of lomitapide should
be taken 12 hours apart from any other
When lomitapide 20 mg was concomitant weak CYP3A4 inhibitors.
co-administered simultaneously with Examples of weak CYP3A4 inhibitors
atorvastatin, a weak CYP3A4 include: alprazolam, amiodarone,
inhibitor, lomitapide AUC and Cmax amlodipine, atorvastatin, azithromycin,
increased approximately 2-fold. bicalutamide, cilostazol, cimetidine,
When the dose of lomitapide was ciclosporin, clotrimazole, fluoxetine,
taken 12 hours apart from fluvoxamine, fosaprepitant, ginkgo,
atorvastatin, no clinically meaningful goldenseal, isoniazid, ivacaftor, lacidipine,
increase in lomitapide exposure was lapatinib, linagliptin, nilotinib,
observed. oestrogen-containing oral contraceptives,
pazopanib, peppermint oil, propiverine,
When lomitapide 20 mg was co- ranitidine, ranolazine, roxithromycin, Seville
administered simultaneously or oranges, tacrolimus, ticagrelor and tolvaptan.
12 hours apart with ethinyl This list is not intended to be comprehensive
estradiol/norgestimate, a weak and prescribers should check the prescribing
CYP3A4 inhibitor, no clinically information of medicinal products to be co-
meaningful increase in lomitapide administered with Lojuxta for potential
exposure was observed. CYP3A4 mediated interactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) lacidipine (HOS-113865) norgestimate (HOS-110544) cilostazol (HOS-111550) cimetidine (HOS-085835) atorvastatin (HOS-086304) alprazolam (HOS-086171) roxithromycin (HOS-127365) propiverine (HOS-127363) peppermint oil (HOS-127362) estradiol (HOS-090751) amlodipine (HOS-086287) azithromycin (HOS-088112) clotrimazole (HOS-090574) bicalutamide (HOS-127356) tolvaptan (HOS-109429) fosaprepitant (HOS-117427) lapatinib (HOS-122565) ivacaftor (HOS-109475) tacrolimus (HOS-085202) linagliptin (HOS-124309) pazopanib (HOS-122551) fluoxetine (HOS-085946) ranitidine (HOS-085660) amiodarone (HOS-085596) fluvoxamine (HOS-085908) ranolazine (HOS-086141) isoniazid (HOS-088590) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage 714d59bc1bbe3ac0c5d4eeaa178f455a97b56caa11d4ced4ec39de50572ee7d0 · Zeichen 2870–5037 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-129263 · Präparat HOS-096703
11
Antimycobacterials
Rifampicin/Dolutegravir Dolutegravir ↓ The dose of dolutegravir is 50 mg twice
AUC ↓ 54% daily when co-administered with
Cmax ↓ 43% rifampicin. As Triumeq is a fixed dose
Cτ ↓ 72% tablet, an additional 50 mg tablet of
(induction of UGT1A1 dolutegravir should be administered,
and CYP3A enzymes) approximately 12 hours after Triumeq
for the duration of the rifampicin co-
administration (a separate preparation of
dolutegravir is available for this dose
adjustment, see section 4.2).
Rifabutin Dolutegravir ↔ No dose adjustment is necessary.
AUC ↓ 5%
Cmax ↑ 16%
Cτ ↓ 30%
(induction of UGT1A1
and CYP3A enzymes)
Anticonvulsants
Carbamazepine/Dolutegravir Dolutegravir ↓ The recommended dose of dolutegravir
AUC ↓ 49% is 50 mg twice daily when co-
Cmax ↓ 33% administered with carbamazepine. As
Cτ ↓ 73% Triumeq is a fixed dose tablet, an
additional 50 mg tablet of dolutegravir
should be administered, approximately
12 hours after Triumeq for the duration
of the carbamazepine co-administration
(a separate preparation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease is 50 mg twice daily when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers. As Triumeq is a fixed dose
enzymes, a similar tablet, an additional 50 mg tablet of
reduction in exposure as dolutegravir should be administered,
observed with approximately 12 hours after Triumeq
carbamazepine is for the duration of the co-administration
expected) with these metabolic inducers (a separate
preparation of dolutegravir is available
for this dose adjustment, see section
4.2).
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage c667a478669bd5d7bf1481bff4152a60605199708e7c92778db166c77cf6e33c · Zeichen 16252–19999 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-129358 · Präparat HOS-096703
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease should be adjusted when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers.
enzymes, a similar
reduction in exposure as Dosing recommendations are provided
observed with in Table 2 (see section 4.2)
carbamazepine is
expected)
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 377acffb9770a7db982e8e184dd5622d08989e157d6cb396dd8e98806885ed5e · Zeichen 15553–16394 im Abschnitt
Wechselwirkungen · Memantine Accord
Memantine Accord 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-129487 · Präparat HOS-096731
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T10:46:00Z · SHA-256 c76a61ebe494f3a1ef4aca5fd8d6f2a66a21407a16a5c2a27ea4d0aee8198d5d · Passage eecb100e0c463a96285723dcee7ad8631137b4a84f7220b63f1dff0b568e31e0 · Zeichen 115–1746 im Abschnitt
Wechselwirkungen · Memantine Accord
Memantine Accord 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-129512 · Präparat HOS-096731
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T10:46:00Z · SHA-256 c76a61ebe494f3a1ef4aca5fd8d6f2a66a21407a16a5c2a27ea4d0aee8198d5d · Passage eecb100e0c463a96285723dcee7ad8631137b4a84f7220b63f1dff0b568e31e0 · Zeichen 115–1746 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.